🕒 Last update: loading…16/11/2026

Stock CervoMed Inc. CRVO

CervoMed Inc. — Investlytic score 1/5 on the five criteria.

-
-
20/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 1/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ✅ Debt passed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -76.88%

Price change 2019 → 2020: 73.91%

Price change 2020 → 2021: -61.25%

Price change 2021 → 2022: -67.35%

Price change 2022 → 2023: 0.53%

Price change 2023 → 2024: -69.33%

Price change 2024 → 2025: 237.61%

Price change 2025 → 2026: -79.24%

Price change 2026 (year to date): -78.95%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.00

Debt/equity < 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.51

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 63.72% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, model verdict (buy, watch, sell) and details of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
CervoMed Inc.–0.00–🔒
Implanet S.A.–14.66+5.0 %–
Valbiotis S.A.–0.73+56.9 %–
Diagnostic Medical Systems S.A.–0.98+7.0 %–
Biosynex S.A.–1.90+35.4 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by CervoMed Inc. over the latest fiscal years.

Revenue
71,667 USD
fiscal year 2013
Net income
-2.5 m USD
fiscal year 2013
Net margin
-3,438.1 %
fiscal year 2013
Market cap
25.6 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
201040,189-8.4 m-20,926.1 %n/a
2011570,476-22.6 m-3,967.9 %+1,319.5 %
2012374,542-6.9 m-1,834.0 %-34.3 %
201371,667-2.5 m-3,438.1 %-80.9 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by CervoMed Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-7.09
risk zone (below 1.81)
Piotroski Score
1 / 9
0 to 3: fragile accounts
DCF Value
0.800 USD
DCF below share price · share price 1.91 USD, gap -57.8 %
Net Debt / EBITDA
0.21 x
low debt
Fiscal year20212022202320242025
Cash and investments37.3 m4.1 m7.8 m38.9 m20.9 m
Total Debt012.4 m000
Net Debt-37.3 m8.3 m-7.8 m-9.0 m-8.2 m
Equity34.9 m-9.0 m7.4 m39.2 m18.2 m
Total assets37.8 m4.2 m10.0 m43.1 m22.9 m
Operating cash flow-14.5 m-2.6 m-7.4 m-16.5 m-23.4 m
Investments (capex)01000
Free cash-flow-14.5 m-2.6 m-7.4 m-16.5 m-23.4 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.66 x
Price / book value1.59 x
Return on Equity (ROE)-164.9 %
Return on Invested Capital (ROIC)-168.4 %
Net margin0.0 %
Debt / equity0.00 x
Current ratio5.37 x
Free cash-flow yield-96.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 16/11/2026.

+

Valuation and competitors

CervoMed Inc. compared with its sector on the same exchange and with its main competitors.

Sector median P/E
20.8
healthcare, Nasdaq
Sector over 10 years
28.2
10-year median, range 20.4 to 45.8

Direct competitors

CompanyMarket cap (USD)P/ENet margin
CervoMed Inc.21.5 mn/a0.0 %
Gain Therapeutics, Inc. GANX43.9 mn/a0.0 %
Adagene Inc. ADAG75.3 mn/a-229.6 %
XBiotech Inc. XBIT57.6 mn/a0.0 %
OS Therapies Incorporated OSTX46.8 mn/a0.0 %
Nutriband Inc. NTRB67.5 mn/a-404.1 %
Adicet Bio, Inc. ACET28.6 mn/a0.0 %
NRx Pharmaceuticals, Inc. NRXP103 mn/a-2,336.5 %
Fortress Biotech, Inc. FBIO61.7 mn/a10.8 %
Sector median (Nasdaq)20.8

Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on 13/11/2026. Competitors: comparable companies named by the data provider.

+

Analyst consensus and forecasts

What the financial analysts covering CervoMed Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
7 analysts

Breakdown of ratings

strong buy 0buy 7hold 0sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 5 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in CervoMed Inc.

Free float
63.5 %
share of freely traded shares

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 07/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 23/05/2008
ISIN code
US15713L1098
Workforce
15
full-time employees
Chief executive
John J. Alam

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about CervoMed Inc.

What is the CervoMed Inc. share price?

Latest recorded price: 1.69 USD on 13/11/2026, for a market cap of 25.6 m USD.

What is the revenue of CervoMed Inc.?

71,667 USD for fiscal year 2013, with net income of -2.5 m USD (net margin -3,438.1 %).

What do analysts say about CervoMed Inc.?

Out of 7 analysts: 7 buy or strong buy, 0 hold, 0 sell or strong sell.

Is CervoMed Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US15713L1098).

How many employees does CervoMed Inc. have?

15 full-time employees according to the latest published profile.

Who runs CervoMed Inc.?

John J. Alam is the company's chief executive.

07

Similar stocks